secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEXX LABORATORIES INC /DE (IDXX)
CIK:        0000874716
Form:       8-K
Filed at:   2026-08-04T10:32:59+00:00
Accession:  0001104659-26-090033
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEXX Laboratories Reports Q2 2026 Revenue of $1,217M and EPS of $4.27, Raises 2026 Outlook
--------------------------------------------------------------------------------

- Revenue grew 10% as reported and 9% organic; CAG Diagnostics recurring revenue grew 11% as reported and 10% organic.
- EPS of $4.27, up 18% as reported and 15% comparable; operating margin increased 140 bps as reported and 110 bps comparable.
- IDEXX inVue Dx installed base surpassed 9,000 instruments, with over 1,600 placements during Q2 2026.
- Narrows 2026 revenue guidance to $4,700M-$4,745M, up $5M at midpoint; raises EPS outlook to $14.69-$14.94.
- Updates 2026 organic revenue growth outlook to 8.5%-9.7% and CAG Diagnostics recurring revenue organic growth to 9.5%-10.7%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874716/000110465926090033/0001104659-26-090033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874716/000110465926090033/tm2622041d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-090033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer